{
  "id": "5e4b64516d0a277941000029",
  "type": "yesno",
  "question": "Is Semagacestat effective for Alzheimer's Disease?",
  "ideal_answer": "No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
    "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
    "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
    "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
    "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
    "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
    "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
    "http://www.ncbi.nlm.nih.gov/pubmed/22087836",
    "http://www.ncbi.nlm.nih.gov/pubmed/28978478",
    "http://www.ncbi.nlm.nih.gov/pubmed/21501112",
    "http://www.ncbi.nlm.nih.gov/pubmed/26064192"
  ],
  "snippets": [
    {
      "text": "However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheimer's disease (AD) was terminated due to unexpected aggravation of cognitive deficits and side effects. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: In participants with mild to moderate AD, high dose semagacestat treatment was associated with greater severity and faster worsening of NPS in a pattern resembling an agitated depression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: The negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26064192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A clinical trial with the wide-spectrum \u03b3-secretase inhibitor semagacestat has, however, demonstrated that global inhibition of all \u03b3-secretases causes serious toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ESULTS: Semagacestat treatment was associated with increased reporting of suspected Notch-related adverse events (gastrointestinal, infection, and skin cancer related). Other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin-related TEAEs, renal and hepatic changes, increased QT interval, and weight loss. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently disclosed Phase III findings on semagacestat indicated that Alzheimer's disease (AD) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent failure of semagacestat in two large Phase III studies questions the value of \u03b3-secretase inhibitors in treating Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ntly disclosed Phase III findings on semagacestat indicated that Alzheimer's disease (AD) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo. Since",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ts from Phase III studies showed that semagacestat failed to slow disease progression, and it was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Furthermore, sem",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rge Phase III clinical trials of semagacestat in mild-to-moderate AD patients were prematurely interrupted because of the observation of a detrimental cognitive and functional effect of the drug. These detrimental ef",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheimer's disease (AD) was terminated due to unexpected aggravation of cognitive deficits and side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, the preliminary equivocal cognitive results obtained with bapineuzumab as well as the detrimental cognitive effects observed with semagacestat, a potent \u03b3-secretase inhibitor, raise the possibility that targeting A\u03b2 may not be clinically efficacious in AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501112",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}